Ilaprazole

Drug Profile

Ilaprazole

Alternative Names: Aldenon; Aldenonc; IY-81149; Noltec; Yi Li An

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Il-Yang
  • Developer Il-Yang; Livzon Group; Takeda
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 01 Jan 2017 Il-Yang Pharm completes a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT02998437)
  • 01 Dec 2016 Il-Yang Pharm initiates a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT02998437)
  • 22 Aug 2014 Ilaprazole is available for out-licensing in North America, Latin America, Europe, Asia as of 22 Aug 2014. http://www.ilyang.co.kr
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top